NO20082695L - 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser - Google Patents

3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser

Info

Publication number
NO20082695L
NO20082695L NO20082695A NO20082695A NO20082695L NO 20082695 L NO20082695 L NO 20082695L NO 20082695 A NO20082695 A NO 20082695A NO 20082695 A NO20082695 A NO 20082695A NO 20082695 L NO20082695 L NO 20082695L
Authority
NO
Norway
Prior art keywords
piperidinyl
treatment
naphthalenyl
oxy
inflammation
Prior art date
Application number
NO20082695A
Other languages
English (en)
Inventor
Simon Tennby Hodgson
Panayiotis Alexandro Procopiou
Maria Victoria Vina Brugarolas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0525897A external-priority patent/GB0525897D0/en
Priority claimed from GB0623217A external-priority patent/GB0623217D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20082695L publication Critical patent/NO20082695L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse angår en forbindelse med formel (I), eller et salt derav: hvor naftalenringen kan være substituert i 2-, 3-, 4-, 5-, 6-, 7- eller 8-stilling med R1 og R1 representerer -CH2CH2COOH eller -CH=C(CH3)COOH, og fremgangsmåter for fremstilling av dem, preparater inneholdende dem, og anvendelse av dem ved behandling av forskjellige sykdommer, så som allergisk rhinitt.
NO20082695A 2005-12-20 2008-06-11 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser NO20082695L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0525897A GB0525897D0 (en) 2005-12-20 2005-12-20 Compounds
GB0623217A GB0623217D0 (en) 2006-11-21 2006-11-21 Compounds
PCT/EP2006/069943 WO2007071691A1 (en) 2005-12-20 2006-12-19 3- (4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] 0xy} phenyl) -1-piperidinyl] carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders

Publications (1)

Publication Number Publication Date
NO20082695L true NO20082695L (no) 2008-09-16

Family

ID=37845266

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082695A NO20082695L (no) 2005-12-20 2008-06-11 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser

Country Status (25)

Country Link
US (1) US7989629B2 (no)
EP (2) EP2157087A1 (no)
JP (2) JP4445570B2 (no)
KR (1) KR20080087102A (no)
AR (1) AR058109A1 (no)
AT (1) ATE449769T1 (no)
AU (1) AU2006328512B2 (no)
BR (1) BRPI0620218A2 (no)
CA (1) CA2634391A1 (no)
CR (1) CR10102A (no)
CY (1) CY1110601T1 (no)
DE (1) DE602006010737D1 (no)
DK (1) DK1963307T3 (no)
EA (1) EA014354B1 (no)
ES (1) ES2337187T3 (no)
HK (1) HK1120265A1 (no)
IL (1) IL191967A0 (no)
MA (1) MA30373B1 (no)
NO (1) NO20082695L (no)
PE (1) PE20071068A1 (no)
PL (1) PL1963307T3 (no)
PT (1) PT1963307E (no)
SI (1) SI1963307T1 (no)
TW (1) TW200730498A (no)
WO (1) WO2007071691A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137858B (zh) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
JP2012531393A (ja) 2009-06-29 2012-12-10 グラクソ グループ リミテッド 新規の医学的使用
JP4785963B2 (ja) 2009-10-09 2011-10-05 キヤノン株式会社 固体撮像装置
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SG11201609276RA (en) 2014-05-12 2016-12-29 Glaxosmithkline Ip No 2 Ltd Pharmaceutical compositions comprising danirixin for treating infectious diseases
KR101640756B1 (ko) 2014-10-28 2016-07-19 이종찬 전동 드릴 장착용 내시경 캡
EP3758689A4 (en) * 2018-03-01 2022-01-12 Ferox Therapeutics LLC METHODS FOR THE PREVENTION AND TREATMENT OF HYPOGLYCEMIA IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
DE69334150T2 (de) 1992-05-14 2008-03-13 Baylor College Of Medicine, Houston Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
CA2192668A1 (en) 1994-06-15 1995-12-21 Harold Francis Hodson Amidino sulfone derivatives for use as inos inhibitors claims
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
DE69918422T2 (de) 1998-03-14 2005-08-11 Altana Pharma Ag Phthalazinone als PDE3/4 Inhibitoren
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
CN1353717A (zh) 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
ES2523930T3 (es) 2000-08-05 2014-12-02 Glaxo Group Limited Éster s-fluorometílico del ácido 6-alfa,9-alfa-difluoro-17-alfa-[(2-furanilcarbonil)oxi]-11-beta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dien-17-carbotioico como agente antiinflamatorio
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
KR20090057477A (ko) 2001-09-14 2009-06-05 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
ATE346058T1 (de) 2002-01-14 2006-12-15 Boehringer Ingelheim Pharma Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
AU2003230700A1 (en) 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
NZ535889A (en) 2002-03-26 2006-03-31 Boehringer Ingelheim Pharma Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003281355A1 (en) 2002-07-08 2004-01-23 Pfizer Products Inc. Modulators of the glucocorticoid receptor
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
DE60322713D1 (de) 2002-08-21 2008-09-18 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
MXPA05002887A (es) 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
US20050245588A1 (en) 2002-09-20 2005-11-03 Amjad Ali Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
JP2006512404A (ja) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
PE20080360A1 (es) 2006-04-20 2008-05-22 Glaxo Group Ltd Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3

Also Published As

Publication number Publication date
TW200730498A (en) 2007-08-16
HK1120265A1 (en) 2009-03-27
ES2337187T3 (es) 2010-04-21
WO2007071691A1 (en) 2007-06-28
AU2006328512A1 (en) 2007-06-28
PE20071068A1 (es) 2007-12-13
DK1963307T3 (da) 2010-04-06
BRPI0620218A2 (pt) 2011-11-01
US20080312280A1 (en) 2008-12-18
JP2009235087A (ja) 2009-10-15
AU2006328512B2 (en) 2011-06-23
PL1963307T3 (pl) 2010-05-31
CA2634391A1 (en) 2007-06-28
JP4445570B2 (ja) 2010-04-07
PT1963307E (pt) 2010-03-03
EA200801342A1 (ru) 2008-12-30
CY1110601T1 (el) 2015-04-29
CR10102A (es) 2008-09-22
EP1963307A1 (en) 2008-09-03
MA30373B1 (fr) 2009-05-04
IL191967A0 (en) 2008-12-29
ATE449769T1 (de) 2009-12-15
AR058109A1 (es) 2008-01-23
JP2009520001A (ja) 2009-05-21
SI1963307T1 (sl) 2010-03-31
KR20080087102A (ko) 2008-09-30
US7989629B2 (en) 2011-08-02
DE602006010737D1 (de) 2010-01-07
EP2157087A1 (en) 2010-02-24
EA014354B1 (ru) 2010-10-29
EP1963307B1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
NO20082695L (no) 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20063382L (no) Nye kinolinderivater
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20084005L (no) Aminderivater
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20055219L (no) Nye forbindelser
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20090327L (no) Nye forbindelser 384
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20090328L (no) Nye forbindelser 385
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20084328L (no) Nye forbindelser
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application